Hellenic Accreditation System

Annex G1/5 to the Certificate No. **1215**-3

SCOPE of ACCREDITATION

for the

Human Molecular Genetics Laboratory

of

National Center for Scientific Research "Demokritos" (NCSR Demokritos)

Tested materials/ products	Types of test/ Properties to be measured	Applied Standards/ Techniques to be used
Molecular Genetics		
1. Peripheral Blood	1. Mutation detection in 41 genes (*APC, ATM, BAP1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, DICER1, FANCM, FH, FLCN, MEN1, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PMS2, PTEN, RAD51C, RAD51D, RB1, RECQL4, RET, SDHB, SDHC, SDHD, SLX4, SMAD4, STK11, TP53, TSC1, TSC2, VHL*) associated with cancer predisposition.	Next Generation Sequencing (NGS) using the commercially available kit Illumina TruSight Cancer panel (Illumina, San Diego, USA) Lab Protocol O.520-3, version 2, 10/2/2020
2. Peripheral Blood	2. Detection of large genomic rearrangements in 41 genes (*APC, ATM, BAP1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, DICER1, FANCM, FH, FLCN, MEN1, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PMS2, PTEN, RAD51C, RAD51D, RB1, RECQL4, RET, SDHB, SDHC, SDHD, SLX4, SMAD4, STK11, TP53, TSC1, TSC2, VHL*) associated with cancer predisposition.	Multiplex Ligation-dependent Probe Amplification, MLPA, using the commercially available kit SALSA MLPA EK1-FAM (MRC-Holland, Amsterdam, the Netherlands) Lab Protocol O.520-3, version 2, 10/2/2020

Site of assessment: **Laboratory permanent premises: Patr. Gregoriou E & 27 Neapoleos Str, 15341, Agia Paraskevi, Greece.**

Approved signatories**: D. Yannoukakos, I. Konstantopoulou, F. Fostira, P. Apostolou.**

This scope of Accreditation replaces the previous one dated 16.10.2024.
The Accreditation Certificate No. **1215**-3, to ELOT EN ISO 15189:2022, is valid until 27.07.2029.

Athens, 16.04.2025

Konstantinou Evangelos Apostolos
CEO of ESYD